Cantor Fitzgerald Analysts Give CytomX Therapeutics (CTMX) a $40.00 Price Target

Cantor Fitzgerald set a $40.00 price objective on CytomX Therapeutics (NASDAQ:CTMX) in a research report sent to investors on Wednesday. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of CytomX Therapeutics from a hold rating to a sell rating in a research note on Monday, February 5th. BidaskClub cut shares of CytomX Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, March 30th. ValuEngine upgraded shares of CytomX Therapeutics from a sell rating to a hold rating in a research note on Monday, April 2nd. Bank of America raised their price target on shares of CytomX Therapeutics from $34.00 to $40.00 and gave the stock a buy rating in a research note on Thursday, March 8th. Finally, Jefferies Group raised their price target on shares of CytomX Therapeutics to $40.00 and gave the stock a buy rating in a research note on Thursday, March 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. CytomX Therapeutics has a consensus rating of Buy and a consensus target price of $38.43.

CytomX Therapeutics opened at $24.82 on Wednesday, according to MarketBeat Ratings. CytomX Therapeutics has a twelve month low of $13.00 and a twelve month high of $35.00. The stock has a market capitalization of $917.06 million, a P/E ratio of -21.40 and a beta of 0.95.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Wednesday, March 7th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.45. CytomX Therapeutics had a negative net margin of 67.88% and a negative return on equity of 92.68%. The business had revenue of $27.07 million during the quarter, compared to analysts’ expectations of $10.70 million. research analysts forecast that CytomX Therapeutics will post -1.47 EPS for the current year.

In other CytomX Therapeutics news, insider Rachel Humphrey sold 23,840 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $30.00, for a total transaction of $715,200.00. Following the completion of the transaction, the insider now owns 54,074 shares in the company, valued at $1,622,220. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Frederick W. Gluck sold 5,000 shares of CytomX Therapeutics stock in a transaction that occurred on Monday, March 26th. The shares were sold at an average price of $31.93, for a total transaction of $159,650.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 123,578 shares of company stock valued at $3,633,036. Corporate insiders own 8.50% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Swiss National Bank raised its stake in shares of CytomX Therapeutics by 6.6% in the first quarter. Swiss National Bank now owns 35,600 shares of the biotechnology company’s stock valued at $1,013,000 after acquiring an additional 2,200 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of CytomX Therapeutics by 28.8% in the first quarter. State Board of Administration of Florida Retirement System now owns 12,706 shares of the biotechnology company’s stock valued at $361,000 after acquiring an additional 2,840 shares during the last quarter. Allianz Asset Management GmbH raised its stake in shares of CytomX Therapeutics by 7.4% in the first quarter. Allianz Asset Management GmbH now owns 58,739 shares of the biotechnology company’s stock valued at $1,671,000 after acquiring an additional 4,036 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of CytomX Therapeutics by 10.4% in the first quarter. New York State Common Retirement Fund now owns 46,897 shares of the biotechnology company’s stock valued at $1,334,000 after purchasing an additional 4,420 shares in the last quarter. Finally, Iguana Healthcare Management LLC increased its holdings in shares of CytomX Therapeutics by 7.1% in the fourth quarter. Iguana Healthcare Management LLC now owns 75,000 shares of the biotechnology company’s stock valued at $1,583,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors own 68.83% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply